1. bookVolumen 35 (2022): Edición 2 (August 2022)
Detalles de la revista
License
Formato
Revista
eISSN
2300-6676
Primera edición
30 May 2014
Calendario de la edición
4 veces al año
Idiomas
Inglés
Acceso abierto

Coumarin derivatives against amyloid-beta 40 – 42 peptide and tau protein

Publicado en línea: 02 Sep 2022
Volumen & Edición: Volumen 35 (2022) - Edición 2 (August 2022)
Páginas: 67 - 74
Recibido: 13 Mar 2022
Aceptado: 17 Jun 2022
Detalles de la revista
License
Formato
Revista
eISSN
2300-6676
Primera edición
30 May 2014
Calendario de la edición
4 veces al año
Idiomas
Inglés

1. Serrano-Pozo A, Das S, Hyman BT. APOE and Alzheimer’s disease: Advances in genetics, pathophysiology, and therapeutic approaches. Lancet Nerol. 2021;20(1):68-80.10.1016/S1474-4422(20)30412-9 Search in Google Scholar

2. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002; 297:353-6.10.1126/science.107299412130773 Search in Google Scholar

3. Dasari M, Espargaro A, Sabate R, Lopez Del Amo JM, Fink U, Grelle G, et al. Bacterial inclusion bodies of Alzheimer’s disease β-amyloid peptides can be employed to study native-like aggregation intermediate states. Chembiochem. 2011;12:407-23.10.1002/cbic.20100060221290543 Search in Google Scholar

4. Mao P, Reddy PH. Aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in Alzheimer’s disease: implications for early intervention and therapeutics. Biochim Biophys Acta. 2011;1812:1359-70.10.1016/j.bbadis.2011.08.005318517221871956 Search in Google Scholar

5. Govoni S, Mura E, Preda S, Racchi M, Lanni C, Grilli M, et al. Dangerous liaisons between beta-amyloid and cholinergic neurotransmission. Curr Pharm Des. 2014;20:2525-38.10.2174/1381612811319999050323859550 Search in Google Scholar

6. Tang BL. Amyloid Precursor Protein (APP) and GABAergic neurotransmission. Cells. 2019;8:550.10.3390/cells8060550662794131174368 Search in Google Scholar

7. Girek M, Szymański P. Tacrine hybrids as multi-target-directed ligands in Alzheimer’s disease: influence of chemical structures on biological activities. Chem Papers. 2018;73:269-89.10.1007/s11696-018-0590-8 Search in Google Scholar

8. Morphy R, Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005;48:6523-43.10.1021/jm058225d16220969 Search in Google Scholar

9. Skalicka-Woźniak K, Orhan IE, Cordell GA, Nabavi SM, Budzyńska B. Implication of coumarins towards central nervous system disorders. Pharmacol Res. 2016;103:188-203.10.1016/j.phrs.2015.11.02326657416 Search in Google Scholar

10. Rao VR. Antioxidant Agents. Advances in structure and activity relationship of coumarin derivatives. London; 2016:137-50.10.1016/B978-0-12-803797-3.00007-2 Search in Google Scholar

11. Wang L, Yin YL, Liu XZ, Shen P, Zheng YG, Lan XR, et al. Current understanding of metal ions in the pathogenesis of Alzheimer’s disease. Transl Neurodegener. 2020;9 :10.10.1186/s40035-020-00189-z Search in Google Scholar

12. Budzynska B, Boguszewska-Czubara A, Kruk-Slomka M, Skalicka-Wozniak K, Michalak A, Musik I, et al. Effects of imperatorin on scopolamine-induced cognitive impairment and oxidative stress in mice. Psychopharmacology (Berl). 2015;232:931-42.10.1007/s00213-014-3728-6 Search in Google Scholar

13. Espargaró A, Medina A, di Pietro O, Muñoz-Torrero D, Sabate R. Ultra rapid in vivo screening for anti-Alzheimer anti-amyloid drugs. Scientific Reports. 2016;6:1-8.10.1038/srep23349 Search in Google Scholar

14. Kowalczyk J, Budzyńska B, Kurach Ł, Pellegata D, Sayed NS, Gertsch J, et al. Neuropsychopharmacological profiling of scoparone in mice. Sci Rep. 2022;12:822.10.1038/s41598-021-04741-3 Search in Google Scholar

15. Kozioł E, Skalicka-Woźniak K. Imperatorin–pharmacological meaning and analytical clues: profound investigation. Phytochem Rev. 2016;15:627-49.10.1007/s11101-016-9456-2 Search in Google Scholar

16. Espargaró A, Sabaté R, Ventura S. Kinetic and thermodynamic stability of bacterial intracellular aggregates. FEBS Letters. 2008;582: 3669-73.10.1016/j.febslet.2008.09.049 Search in Google Scholar

17. Espargaró A, Pont C, Gamez P, Muñoz-Torrero D, Sabate R. Amyloid pan-inhibitors: One family of compounds to cope with all conformational diseases. ACS Chem Neurosci. 2019;10:1311-7.10.1021/acschemneuro.8b00398 Search in Google Scholar

18. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, et al. Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer’s disease. Am J Pathol. 1999;155:853-62.10.1016/S0002-9440(10)65184-X Search in Google Scholar

19. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535-9.10.1038/416535a11932745 Search in Google Scholar

20. Li JJ, Dolios G, Wang R, Liao FF. Soluble beta-amyloid peptides, but not insoluble fibrils, have specific effect on neuronal microRNA expression. PLoS One. 2014;9(3):e90770.10.1371/journal.pone.0090770394247824595404 Search in Google Scholar

21. Yang J, Zhu B, Yin W, Han Z, Zheng C, Wang P, et al. Differentiating Aβ40 and Aβ42 in amyloid plaques with a small molecule fluorescence probe. Chem Sci. 2020;11:5238-45.10.1039/D0SC02060E Search in Google Scholar

22. Gu L, Guo Z. Alzheimer’s Aβ42 and Aβ40 peptides form interlaced amyloid fibrils. J Neurochem. 2013;126:305.10.1111/jnc.12202371683223406382 Search in Google Scholar

23. Takomthong P, Waiwut P, Yenjai C, Sripanidkulchai B, Reubroycharoen P, Lai R, et al. Structure-activity analysis and molecular docking studies of coumarins from Toddalia asiatica as multifunctional agents for Alzheimer’s disease. Biomedicines. 2020;8(5):107.10.3390/biomedicines8050107727774832370238 Search in Google Scholar

Artículos recomendados de Trend MD

Planifique su conferencia remota con Sciendo